Previous 10 | Next 10 |
Confirmed overall response rate improves to 41% at 100mg BID dose level Continued favorable safety and tolerability profile observed in heavily pre-treated patients Pivotal study initiation expected 2H 2022 following food effect study CAMBRIDGE, Mass., March 28, 20...
Cullinan Oncology press release (NASDAQ:CGEM): Q4 GAAP EPS of -$0.74 misses by $0.30. Cash, cash equivalents and investments were $430.9 million as of December 31, 2021 For further details see: Cullinan Oncology GAAP EPS of -$0.74 misses by $0.30
CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 2022 CLN-049 and CLN-619 patient dosing initiated in December 2021 for first-in-human clinical trials; initial clinical data expected by mid-2023 Portfolio advanc...
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, will provide a regulatory update on CLN-081 during a we...
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients, today announced that it will be participating in th...
Five abstracts selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 Data highlight progress on Cullinan Oncology’s pipeline of therapeutic candidates CLN-049 (Florentine), CLN-619 (MICA), CLN-617 (Amber), CLN-978 (Nex...
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that Jeffrey (Jeff) Jones, ...
The following slide deck was published by Cullinan Oncology, Inc. in conjunction with this event. For further details see: Cullinan Oncology (CGEM) Investor Presentation - Slideshow
CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will be participating in SVB Leerink’s 11 th Annual Global Healthcare Conference, being held virtually February 14-18, 2022. Nadim A...
Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ: CGEM) (...
News, Short Squeeze, Breakout and More Instantly...
Cullinan Oncology Inc. Company Name:
CGEM Stock Symbol:
OTCMKTS Market:
Cullinan Oncology Inc. Website:
2024-06-30 11:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after prior treatment with amivanta...
2024-05-29 21:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...